Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical Intraepithelial Neoplasia Grade 2/3: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Cervical Intraepithelial Neoplasia Grade 2/3: 2 US clinical trials tracked, none currently recruiting.
Cervical Intraepithelial Neoplasia Grade 2/3 is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Gynecologic Oncology Group, running 1 of these trials.
Enrollment posture brief
Registry condition cervical-intraepithelial-neoplasia-grade-23
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Cervical Intraepithelial Neoplasia Grade 2/3 has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cervical Intraepithelial Neoplasia Grade 2/3 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cervical Intraepithelial Neoplasia Grade 2/3 is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
Gynecologic Oncology Group
NCT00081263
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02354534
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cervical Intraepithelial Neoplasia Grade 2/3 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cervical Intraepithelial Neoplasia Grade 2/3 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cervical Intraepithelial Neoplasia Grade 2/3 page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Cervical Intraepithelial Neoplasia Grade 2/3 trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Gynecologic Oncology Group sponsors the most Cervical Intraepithelial Neoplasia Grade 2/3 trials on record, review their full trial history before evaluating a specific study. See Gynecologic Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cervical Intraepithelial Neoplasia Grade 2/3 condition card totals 2 registered trials; most-linked intervention Artesunate Suppositories; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.